Tharimmune, Inc. announced on March 4, 2025, the expansion of its product pipeline with HS1940. This is a dual-target multispecific biologic engineered to bind to both Programmed Death-1 (PD-1) and Vascular Endothelial Growth Factor (VEGF) receptors.
HS1940 utilizes the company's proprietary EpiClick™ Technology, a versatile multispecific antibody engineering platform. This technology aims to target and bind to 'undruggable epitopes' differently than full-sized antibodies.
The introduction of HS1940 represents a key expansion of Tharimmune's product pipeline in immuno-oncology. It underscores the company's commitment to developing differentiated approaches to address high-unmet-need conditions in cancer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.